Ganetespib Phase 3 2014??? Will they need more cash?
Slide 9 in the investor presentation shows Ganetespib delayed until 2014, and just $44 million in cash. That almost certainly means this run is setting up for dilution/secondary offering. How else do they survive for another 1.5 years on $44 million?
Do you get anything right? Nothing is delayed. The phase III part of the NSCLC trial will begin in Q4 of 2012. Why would anyone think the trial would be finished before 2014? I guess only someone stupid enough to publicly state multiple times on a message board that a drug in phase II trials would be approved by the FDA in 6 months, and state that BEFORE any data from the trial was released, might believe that. Do you know anyone who fits that profile? Nothing that SNTA said indicated the phase III part of the NSCLC trial would be done before 2014.
SNTA added $25 million a few months ago so they have close to $70 million. Good phase II data will make raising cash relatively painless.